Trabectedin
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
Trabectedin is a marine-derived antineoplastic agent approved for treatment of advanced soft tissue sarcomas including liposarcoma and leiomyosarcoma. It binds to the minor groove of DNA, interfering with transcription and DNA repair mechanisms. The drug has shown particular efficacy in myxoid liposarcoma and dedifferentiated liposarcoma subtypes.
Indications & Therapeutic Use
advanced soft tissue sarcoma, liposarcoma, leiomyosarcoma, relapsed ovarian cancer
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Trabectedin — GNH India
82 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Trabec
1mg
Trabectedin
EU
Trabectedin Accord
EU
Trabectedin Eg
EU
Trabectedin Ever Pharma
EU
Trabectedin Genus Pharmaceuticals
EU
Trabectedin Ratiopharm
EU
Trabectedin Stada
EU
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Trabectedin
| Generic Name | trabectedin |
| Brands | 1 brand available |
| Active Ingredient | trabectedin |
| Drug Class | advanced soft tissue sarcoma |
| Manufacturer | Janssen/PharmaMar |
| Dosage Forms | IV infusion 0.25mg/mL, 1mg/mL (1mg/4mL, 1mg/20mL vials) |
| Medical Code | L01CX01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00061984 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes